December 26, 2007
Dr. Ping Sheng, Head of the Department of Physics and Director of the Institute of Nano Science and Technology, Hong Kong University of Science and Technology, 3-24-04
Dr. Ping Sheng is Head of the Department of Physics and, previously, Director of the Institute of Nano Science and Technology at the Hong Kong University of Science and Technology. He is also a Professor of Physics. Dr. Sheng is a Fellow of the American Physical Society, and Member of the Asia Pacific Academy of Materials. In 2002, he was awarded Technology Leader of the Year by the Sing Tao Group. Dr. Sheng has published over 200 papers and presented over 100 keynote or invited talks at international meetings and conferences. He also has 10 U.S. patents and is the author of a monograph on Wave Scattering, Localization, and Mesoscopic Phenomena.
Dr. Sheng's research is in the area of condensed matter physics. He has pioneered in the study of liquid crystal–substrate interaction while at the RCA David Sarnoff Research Laboratory, and established the mechanisms of charging-energy correlated hopping and fluctuation-induced tunneling conduction in disordered materials. While at Exxon Corporate Research Center from 1979-1994, Dr. Sheng's interest broadened into wave interaction and scattering in disordered systems, and porous media. The study of nanotechnology became his main focus after joining HKUST in 1994, where he led efforts in the discovery of superconducting behavior in ultrathin carbon nanotubes, and the giant electrorheological effect in suspensions of nanoparticles. Dr. Sheng is the inventor of locally resonant sonic materials that can break the mass density law in shielding low frequency sound.
The Institute of Nano Science and Technology (INST), established in 2001 with Dr. Sheng as the founding Director, is the first such research institute in Hong Kong. Its mission is to carry out fundamental research and innovation in nanoscience and technology. Besides the accomplishments in carbon nanotubes and electrorheological fluids, which were reported worldwide in the Washington Post, New Scientist, Science Now, Nanotechweb, and PhysicsWeb, INST achievements include the discovery of room temperature UV lasing from zinc oxide nanocrystals, the discovery of the giant Hall effect in granular metal films, and commercialization of the visible-blind UV detector based on semiconductor heterostructures.
Dr. Jun Wu, Co-founder and Chief Scientific Officer, Shanghai Genomics, 5-26-04
Shanghai Genomics, Inc., a leader of the Chinese biopharmaceutical industry, was founded and is managed by biotechnology professionals returning from the United States. Its mission is to develop novel therapeutic solutions for major diseases threatening the Chinese population, such as liver cirrhosis, acute lung injury/fibrosis, and infectious diseases. The first round of investors included two venture capital firms in China, Shanghai Venture Capital and Zhangjiang Hi-Tech Park Corporation. Shanghai Genomics is privately owned and headquartered at Zhangjiang Hi-Tech Park, Pudong New Area of Shanghai, China. The company has 67 employees and occupies a 30,000-square-foot facility. Shanghai Genomics provides contract research services and genomics/proteomics research tools and reagents to biotech/pharmaceutical companies worldwide. The services include antibody production, antibody screening and immunohistochemistry, recombinant protein production and purification, full-length gene cloning, and Q-PCR and PCR-based gene expression profiling.
Dr. Jun Wu is the co-founder of Shanghai Genomics Inc. He attended Shanghai Medical University as a medical student and later continued his undergraduate studies at San Jose State University in the United States. In 1991, he received his B.S. degree in Microbiology and Immunology. In 1997, he received his doctoral degree at University of California, San Francisco. Later, he joined DNAX Research Institute and Rigel Pharmaceuticals. Dr. Wu is an expert in lymphocyte signal transduction and tumor immunology.